A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Erlotinib (Primary) ; Selumetinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Aug 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 21 Nov 2014 Results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History